GSK Lotronex Risk Management Plan Should Not Be Altered, Cmte. Says
Executive Summary
GlaxoSmithKline's risk management program for Lotronex should not be altered until further data is collected, FDA's Drug Safety & Risk Management Advisory Committee recommended May 5
You may also be interested in...
Wellbutrin Offers Optimistic Case Study For Tysabri
The regulatory and commercial history of the antidepressant brand Wellbutrin may be one precedent for Biogen Idec and Elan to emulate in attempting to salvage the multiple sclerosis therapy Tysabri
Wellbutrin Offers Optimistic Case Study For Tysabri
The regulatory and commercial history of the antidepressant brand Wellbutrin may be one precedent for Biogen Idec and Elan to emulate in attempting to salvage the multiple sclerosis therapy Tysabri
Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs
Pain Therapeutics believes its low-dose oral naltrexone will offer a more positive risk-benefit profile and broader efficacy compared to marketed irritable bowel syndrome therapies